Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
126M
-
Number of holders
-
90
-
Total 13F shares, excl. options
-
59.3M
-
Shares change
-
-7.45M
-
Total reported value, excl. options
-
$49.2M
-
Value change
-
-$6.33M
-
Put/Call ratio
-
0.31
-
Number of buys
-
28
-
Number of sells
-
-59
-
Price
-
$0.83
Significant Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) as of Q3 2024
128 filings reported holding KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share as of Q3 2024.
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) has 90 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 59.3M shares
of 126M outstanding shares and own 46.87% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (7.65M shares), Eversept Partners, LP (5.55M shares), Palo Alto Investors LP (5.1M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (4.32M shares), BlackRock, Inc. (3.64M shares), CITADEL ADVISORS LLC (3.1M shares), MARSHALL WACE, LLP (2.08M shares), Avidity Partners Management LP (2.02M shares), BNP PARIBAS FINANCIAL MARKETS (1.98M shares), and GSA CAPITAL PARTNERS LLP (1.78M shares).
This table shows the top 90 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.